Cargando…
A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients
INTRODUCTION: Selexipag, an oral nonprostanoid prostaglandin receptor agonist, has led to reduced morbidity and mortality in adults with pulmonary arterial hypertension (PAH). While the adult literature has been extrapolated to suggest selexipag as an oral treatment for severe pediatric pulmonary hy...
Autores principales: | Youssef, David, Richards, Susan, Lague, Sabine, Sheppard, Catherine, Smith, Jenna, Vorhies, Erika, Hosking, Martin, Pietrosanu, Matthew, Bates, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011093/ https://www.ncbi.nlm.nih.gov/pubmed/36925667 http://dx.doi.org/10.3389/fped.2023.1055158 |
Ejemplares similares
-
A North American, single-center experience implanting fenestrated atrial devices and atrial flow regulators into a heterogeneous group of pediatric pulmonary hypertension patients
por: Youssef, David Edward, et al.
Publicado: (2023) -
Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience
por: Youssef, David Edward, et al.
Publicado: (2023) -
Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023) -
Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
por: Faircloth, Jenna M., et al.
Publicado: (2023) -
An Adolescent Patient With Idiopathic Pulmonary Arterial Hypertension Weaned Off Intravenous Epoprostenol Following Treatment With Selexipag: A Case Report
por: Chida-Nagai, Ayako, et al.
Publicado: (2022)